5rd edition of the iCEPS Conference, May 18-20, 2017, Montpellier, France 

 

The International Conference on Non-Pharmacological Interventions (NPIs)

Affiche-EN-iCEPS-Conference-2017-Montpellier

Opening Ceremony

For the Occitanie Region, Michel BOUSSATON, Conseiller Régional, délégué à la Santé, à la Silver Economy, et aux Formations Sanitaires et Sociales.

For the City Hall of Montpellier and the Montpellier Metropole, Chantal MARION, Présidente déléguée de la commission Développement économique enseignement supérieur et recherche, Innovation, International, Artisanat

For the University of Montpellier, Jacques MERCIER, Président du Conseil Scientifique

For the University Paul-Valéry Montpellier 3, Denis BROUILLET, Directeur de l’Ecole Doctorale 60

Plenary Lectures

Lectures accepted by the Scientific Committee

ACCESS TO PLENARY LECTURE PROGRAM

Posters

Posters accepted by the Scientific Committee

ACCESS TO POSTERS PROGRAM

Workshops

Workshops accepted by the Scientific Committee

ACCESS TO WORKSHOPS PROGRAM

Session Open to the Public

Natural Medicines, Complementary Medicines, Alternative medicines: What are we talking about exactly?

Affiche grand public w2-01

ACCESS TO PUBLIC SESSION PROGRAM

Registration

Non-Pharmacological Interventions (NPIs)

NPI-Taxonomy-CEPSPlatform-2017

Definition of NPIs

Non-Pharmacological Interventions (NPIs)

NPIs are science-based and non invasive interventions on human health. They aim to prevent, treat, or cure health problems. They may consist in products, methods, programs or services whose contents are known by users. They are linked to biological and/or psychological processes identified in clinical studies. They have a measurable impact on health, quality of life, behavioral and socioeconomic markers. Their implementation requires relational, communicational and ethical skills.

A major issue

We are all familiar with people who have enjoyed the health benefits of an NPI. Nevertheless, these cases do not amount to solid evidence. The mere satisfaction of an NPI happy few cannot be generalized to the general public. Could these outcomes just be the result of a placebo effect? Are they applicable at the same “doses” to other people with the same disorders? For now, academic societies and state health authorities feel that the studies available in the scientific and medical literature do not provide sufficient evidence. They argue that what has been brought forth is merely proof of concept. As a result, policy makers and health industry financial decision-makers remain skeptical. These key players are encouraging innovators to come forward with additional evidence for the efficacy and the cost/effectiveness of NPIs in order to improve their visibility, and, ultimately, to garner more substantive private and public financial support for them.

The role of NPIs

Are NPIs general consumer products or health products, general or care services, education programs or medical devices? Should they be freely available for sale or only via medical prescription? Are they designed to heal, cure, or alleviate chronic pain? Should they be used for relaxation, to increase autonomy, improve of quality of life and/or make people happy? Should for the costs of NPIs be fully or partially reimbursed? Should we monitor their use? Should we verify their toxicity and interference with conventional biological treatments? What better exchange forum than an international conference to share opinions and experiences?

``Is mere individual satisfaction evidence of NPI efficacy?``

Videos 2015

Why this international Conference in Montpellier and Montreal?

Demonstrating the efficacy of NPIs requires debates and multidisciplinary solutions. NPIs span various scientific disciplines, from biological sciences to human and social sciences, from epidemiology to engineering sciences, from medicine to ethics, from new technologies to e-Health, from economics to legal sciences. This proactive interaction and collaboration will prompt the development and the validation of innovations expected by industry players, patients, professionals and decision makers.

Montpellier Metropole is renowned for its historical excellence in the fields of health and human sciences, and for its modern capacity to bring the two together. Non-pharmacological interventions are at the heart of this juncture. Around Montpellier itself, the French Region of Occitanie hosts a variety of proactive university laboratories and health-related companies. Healthcare institutions are also highly involved in clinical research. This economic and research cluster stimulates innovation and clinical research on the rehabilitation of patients suffering from chronic diseases and on health prevention programs. It also fosters social economy and solidarity efforts, as well as e-Health developments.

Montreal is often referred to as “Canada’s Cultural Capital.” Internationally renowned for its rich, vibrant cultural activities and year-round festivals, it combines the modern features of a major metropolis with the historical charm and history of Europe. It is a major hub of biomedical research and higher education (boasting 4 major universities including 2 medical schools – McGill and Universite de Montreal). As Canada’s second largest city, it remains an important center of commerce, education, technology, biotechnology, health research, and world affairs.

Organization

Platform CEPS, a Hub for Clinical Trials on NPIs International Behavioral Trials Network

Persons in charge

Isabelle Boulze, Jerome Maitre, Gregory Ninot, Jean-Louis Pujol, Sylvie Rapior Platefom CEPS, Universities of Montpelier, France
Simon Bacon, Kim Lavoie, MCMC, Montreal, Canada

Persons in charge

Phone: 0033 467 145 497 contact@cepsplatform.eu

Steering committee

Sylvain Agier, Jean Bilard, Isabelle Boulze, Gérard Bourrel, Marie-Virginie Calmels, Monica Cappellini, François Carbonnel, Mario Fernandez, Adeline Gomez, Aurélie Gerazine, Aline Herbinet, Guillaume Lacoste, Estelle Guerdoux-Ninot, Michel Launay, Anne Laurent, Kim Lavoie, Béatrice Lognos, Cécile Maestracci, Francis Maffre, Jérôme Maitre, Sophie Martin, Jeanne Michaux, Laurent Munilla, Grégory Ninot, Patrick Poucheret, Jean-Louis Pujol, Xavier Quantin, Sylvie Rapior, Thierry Rousset, Raphaël Trouillet, Alain Warnery.

Scientific committee

Stéphane Adam, François Alla, Antoine Avignon, Simon Bacon, Marie Baqué-Juston, Vickie Baracos, Laurent Bègue, Pierre-Louis Bernard, Claudine Berr, Hubert Blain, Franck Bonnetain, Isabelle Boulze, Jean Bourbeau, Gérard Bourrel, Jean Bousquet, Denis Brouillet, Stacey Callahan, François Carré, Anne-Sophie Cases-Lacour, Arnaud Castelltort, Franck Chauvin, Geneviève Chêne, Susan Czajkowski, Sara Dauchy, Fabienne D’Arripe-Longueville, Cyrille Delpierre, Gérard Dray, Béatrice Fervers, Francoise Fons, Ken Freedland, Christophe Gernigon, Isabelle Gremy, Estelle Guerdoux-Ninot, Thibault Guiraud, Maurice Hayot, Christian Herrisson, Anne Laurent, Kim Lavoie, Paul Landais, Sophie Martin, Jacques Mercier, Paul Montgomery, Grégory Moullec, Grégory Ninot, Christian Périgaud, Patrick Poucheret, Lynda Powell, Jean-Louis Pujol, Xavier Quantin, Sylvie Rapior, Lise Rochaix, Hélène Sancho-Garnier, Pierre Senesse, Daniel Serin, Anne Stoebner-Delbarre, Joel Swendsen, Raphaël Trouillet, Fernand Vicari, Anne Vuillemin, Marc Ychou.

Organisation

Logo Plateforme CEPS Evolution-07
ibtn

Academic Partners

eu-eng
ue
logo-occitanie
montpellier metropole
ministere_enseignement_sup
Logo ville
Logo-UM
LOGO_VERT_VF
logo COMUE

Others Partners

CARSAT
Siric-Montpellier
th
Logo_Fondation_ARC_pour_la_recherche_sur_le_cancer
ICM-light
CHRU-Montpellier-Logo
Transferts-logo
UdeM_Hexa
FRENCH TECH_fond blanc
SmallLogo

Others Supports

Logo-OBESINOV-vectorisé[1]
INDEX QUERTANT ORG
LOGO bodynovv-01
logo_green-title-w-slogan